AlveoGene’s Mission is to transform respiratory disease outcomes using inhaled gene therapy.
Our #InGenuiTy® platform enables us to deliver our proprietary self-inactivating lentiviral vector based products directly to the lung via nebulisation treating disease locally, efficiently, and safely where it’s clinical impact and patient benefit can be the greatest.
We focus on respiratory diseases of high value and unmet medical need, developing first-in-class and best-in-class products including Alpha-1 Antitrypsin Deficiency (AATD), Neonatal Profound Surfactant Protein Deficiencies (SP-B and ABCA3), and Idiopathic pulmonary Fibrosis (IPF).
To view our presentation from the Oxford-Harrington 2024 Rare Disease Day Webinar hosted on Wednesday, Feb. 28, 2024 please click the link below.
AlveoGene starts at 9 mins 15 secs.
For for more information or to arrange a meeting please email us at [email protected]
